Safety of ondansetron loading doses in children with cancer

Supportive Care in Cancer

Volumn 16, Issue 5, 2008, Pages 469-475

  Hasler, Susann B ^a   Hirt, Andreas ^a   Ridolfi Luethy, Annette ^a   Leibundgut, Kurt K ^a   Ammann, Roland A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Chemotherapy; Children; Emesis; Nausea; Ondansetron loading dose

Indexed keywords

ONDANSETRON;

ABDOMINAL PAIN; ADOLESCENT; ALLERGIC REACTION; ARTICLE; CANCER PATIENT; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG SAFETY; DYSPHAGIA; EDEMA; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPOTENSION; INJECTION SITE REACTION; LEUKEMIA; LOGISTIC REGRESSION ANALYSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; VISUAL IMPAIRMENT;

ADOLESCENT; ANTIEMETICS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; NAUSEA; NEOPLASMS; ONDANSETRON; RETROSPECTIVE STUDIES; SWITZERLAND; TIME FACTORS; VOMITING;

EID: 41849083463     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0338-4     Document Type: Article

References (23)

1. Antonarakis ES, Evans JL, Heard GF, Noonan LM, Pizer BL, Hain RD (2004) Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence? Pediatr Blood Cancer 43:651-658
2. Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciali G, Di Maio M, Andrea B, Deuson RR (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179-185
3. Ballatori E, Roila F, Ruggeri B, Porozzi S, Iannopollo M, Soru G, Cruciali G, Daniele B, Locatelli MC, Pellissier J, Deuson R (2007) The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer 15:31-38
4. Berde CB, Billett AL, Collins JJ (2006) Symptom management in supportive care. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology, 5th edn. Lipincott Williams and Wilkins, Philadelphia, pp 1348-1379
5. 2. Eur J Cancer 32A:1744-1748
6. Culy CR, Bhana N, Plosker GL (2001) Ondansetron: a review of its use as an antimetic in children. Paediatr Drugs 3:441-479
7. Davis M, Maida V, Daeninck P, Pergolizzi J (2007) The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer 15:63-71
8. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055-1061
9. Jones E, Tatsuki K, Ho RH, Kuttesch J, Shankar S, Whitlock JA, Cartwright J, Frangoul H (2007) Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. Pediatr Blood Cancer 48:330-332
10. Khalil SN, Roth AG, Cohen IT, Simhi E, Ansermino JM, Bolos ME, Coté CJ, Hannallah RS, Davis PJ, Brooks PB, Russo MW, Anschuetz GC, Blackburn LM (2005) A double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesia. Anesth Analg 101:356-361
11. Komada Y, Matsuyama T, Takao A, Hongo T, Nishimura Y, Horibe K, Sakurai M (1999) A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy. Eur J Cancer 35:1095-1101
12. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947
13. Nahata MC, Hui LN, Koepke J (1996) Efficacy and safety of ondansetron in pediatric patients undergoing bone marrow transplantation. Clin Ther 18:466-476
14. National Cancer Institute, Cancer Therapy Evaluation Program (2004) NCI Guidelines: adverse event reporting requirements. www.ctep.cancer.gov
15. Parker RI, Prakash D, Mahan RA, Giugliano DM, Atlas MP (2001) Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. J Pediatr Hematol Oncol 23:578-581
16. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754-760
17. Ruff P, Paska W, Goedhals L, Pouillart P, Riviere A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 51:113-118
18. Sandoval C, Corbi D, Strobino B, Fevzi Ozkaynak M, Tugal O, Jayabose S (1999) Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. Cancer Invest 17:309-313
19. Seynaeve C, Schuller J, Buser K, Porteder H, van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Paes D, de Mulder PHM (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 66:192-197
20. Small BE, Holdsworth MT, Raisch DW, Winter SS (2000) Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol 22:125-132
21. Stevens RF (1991) The Role of ondansetron in paediatric patients: a review of three studies. Eur J Cancer 27:S20-S22
22. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28
23. US Department of Health and Human Services (2003) Common Terminology Criteria for Adverse Events v3.0 (CTCAE)